Volume 37 Issue 9, September 2019

Despite dazzling lab demonstrations, robust and viable clinical interventions using brain–computer interfaces remain some way off.

Non-invasive stimulation of the brain is being touted to promote health and well-being and for ‘curing’ disease, but the mechanistic underpinnings of the devices remain unclear.

A process for the non-arbitrary determination of obviousness based on examining actual patenting practices of large groups could improve outcomes.

Recent patents related to the translation and communication of neural signals.

Tissue-like electronic interfaces that form stable long-term interfaces in the brain will enable treatment of chronic neurological and psychiatric diseases.

Anikeeva and colleagues review the state of the art in technologies that enable discoveries of brain function and the development of novel therapeutic approaches.

Advances in deep brain stimulation technologies are poised to improve outcomes in the clinic.

A machine learning model based on data from primary human T cells accurately predicts repair outcomes after CRISPR–Cas9 editing.

A machine learning model allows the identification of new small-molecule kinase inhibitors in days.

Engineered variants of DNA base editors have reduced RNA off-target editing while retaining DNA on-target efficiency.

BiTE-secreting CAR-T cells overcome antigen escape from EGFRvIII-targeted therapy for glioblastoma.

Cellular RNAs are edited with high specificity using engineered ADAR-recruiting RNAs.

Improved base editors are generated by continuous evolution.

A DNA-based amplification scheme enables highly multiplexed immunofluorescence imaging

Patients with unknown disease can serve as an educational catalyst in biomedical sciences to create strong synergy between healthcare, research and undergraduate education, with the goal of fostering translational medicine and helping patients.

A sample of goings-on in and around the biotech and pharmaceutical industry.